As we follow the journey of various neoantigen and neoepitope approaches from start-up and preclinical research through to the clinic, it’s been interesting to see how different companies and academic research groups have chosen to consider their R&D strategies.
Some of the companies we’ve interviewed and highlighted in this space include Neon Therapeutics, BioNTech, Gritstone, and newcomer, Achilles Therapeutics, along with various academic programs such as George Coukos’s neoepitope vaccine approach in Lausanne.
After we first spoke with Gritstone a couple of years ago, things seemed to go a bit quiet on the western front while Neon, BioNTech, and Achilles all had news to talk about. It’s always hard to choose from rock-paper-scissors and this may well be another modern twist of that genre until clinical data proves otherwise.
That all changed with more data being presented by the California-based biotech recently, plus patients are also being enrolled into their first neoantigen clinical trial.
At a recent conference, we caught up with their CMO, Dr Raphael Rousseau, to find out more about where they are and importantly, where they’re headed…